Antimicrobial Development Could Benefit From Smaller Clinical Trials – FDA
Executive Summary
Upcoming FDA guidances on antimicrobial drug development will address ways to reduce clinical trial size, Center for Drug Evaluation & Research Antimicrobial Drug Development & Resistance Initiatives Lead Medical Officer John Powers, MD, said
You may also be interested in...
Past FDA Action Is Not Necessarily Predictive Of Future Behavior – Temple
Sponsors should not assume clinical trials are immune from evaluation according to updated efficacy standards, even if parameters are initially agreed upon with the agency
Past FDA Action Is Not Necessarily Predictive Of Future Behavior – Temple
Sponsors should not assume clinical trials are immune from evaluation according to updated efficacy standards, even if parameters are initially agreed upon with the agency
Antibiotics Should Be One Step On FDA’s “Critical Path,” Lilly VP Says
Antibiotic development is an ideal FDA "Critical Path" opportunity due to the lack of antitrust concerns surrounding the therapeutic category, Lilly VP-Scientific Affairs Gail Cassell, PhD, told the FDA Science Board Advisory Committee April 22